President And CEO Of Denali Therapeutics Sold $1.00 Million In Stock
Ryan Watts, President and CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new SEC filing.
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $99
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $100 to $99.
Denali Therapeutics Q2 EPS $(0.50) Up From $(0.56) YoY, Sales $22.94M Up From $5.85M YoY
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.50) per share. This is a 10.71 percent increase over losses of $(0.56) per share from the same period last year. The company reported $22.94 million in
48 Stocks Moving In Monday’s Mid-Day Session
Gainers
Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The stock is also trading higher in sympathy with the price of Bitcoin.
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $105
HC Wainwright & Co. analyst Andrew Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $95 to $105.
Denali’s Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome
Denali Therapeutics Inc (NASDAQ:DNLI) announced additional interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310) for the central nervous system…
Denali Therapeutics To Present Interim Data Phase 1/2 Study Of ETV:IDS For Potential Treatment Of Hunter Syndrome At MPS 2021
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced its
Denali-Biogen Parkinson’s Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug…